Spectre of widespread breast explantations returns with PIP recall
This article was originally published in Clinica
Executive Summary
The scale of the potential impact of French investigations into breast implants manufactured by Poly Implant Prothèse (PIP) has begun to emerge, as alarm over the potential need to explant tens of thousands of women is spreading internationally.
You may also be interested in...
Medtechs Must Act Fast On New EU Regulations Or Face Gridlock
Following the recent vote in the European Parliament, the EU has finally adopted the Medical Device and IVD Regulations that were proposed back in September 2012. The texts, vastly longer and more complex than the three directives they are replacing, will establish a tougher regulatory code for the next decade or more, but where are the likely pressure points for industry and how can manufacturers prepare?
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.